Halozyme Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Halozyme Therapeutics Inc 公司

Halozyme Therapeutics, Inc. 是一家生物制药公司，致力于开发颠覆性解决方案，以改善新兴和成熟疗法的患者体验和疗效。该公司的 ENHANZE 药物输送技术采用专有酶 rHuPH20，其经过商业验证的解决方案用于促进注射药物和液体的皮下 (SC) 输送，重点是减轻患者的治疗负担。该公司还利用其先进的自动注射器技术为自己或与合作伙伴开发、制造和商业化药物-设备组合产品。该公司拥有两种商业专有产品 Hylenex 和 XYOSTED，与多家制药公司合作开发商业产品并正在进行产品开发计划。该公司营销和销售 Hylenex 重组体，这是 rHuPH20 的一种配方。该公司营销和销售其专有产品 XYOSTED，用于成年男性的睾酮替代疗法 (TRT) 的 SC 给药。

公司简介

公司代码HALO

公司名称Halozyme Therapeutics Inc

上市日期Jan 30, 2003

CEODr. Helen I. Torley

员工数量350

证券类型Ordinary Share

年结日Jan 30

公司地址12390 El Camino Real

城市SAN DIEGO

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编92130

电话18587948889

网址https://www.halozyme.com/

公司代码HALO

上市日期Jan 30, 2003

CEODr. Helen I. Torley

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Helen I. Torley

President, Chief Executive Officer, Director

733.72K

--

Mr. Matthew L. (Matt) Posard

Independent Director

74.04K

+5.96%

Ms. Nicole Labrosse

Chief Financial Officer, Senior Vice President

31.90K

--

Dr. Mahesh Krishnan, M.D.

Independent Director

--

Ms. Moni Miyashita

Independent Director

--

Mr. Jeffrey W. (Jeff) Henderson

Independent Chairman of the Board

--

Mr. Mark Snyder

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

--

Ms. Bernadette M. Connaughton

Independent Director

--

Ms. Barbara Duncan

Independent Director

--

Ms. Tram Bui

Vice President - Investor Relations and Corporate Communications

--

名称

名称/职务

职务

持股

持股变动

Dr. Helen I. Torley

President, Chief Executive Officer, Director

733.72K

--

Mr. Matthew L. (Matt) Posard

Independent Director

74.04K

+5.96%

Ms. Nicole Labrosse

Chief Financial Officer, Senior Vice President

31.90K

--

Dr. Mahesh Krishnan, M.D.

Independent Director

--

Ms. Moni Miyashita

Independent Director

--

Mr. Jeffrey W. (Jeff) Henderson

Independent Chairman of the Board

--

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Royalties

168.19M

63.50%

Sales of proprietary products

36.34M

13.72%

Sales of bulk rHuPH20

27.02M

10.20%

Sales-based milestones

15.00M

5.66%

Sales of device partnered products

14.68M

5.54%

Other

3.63M

1.37%

暂无数据

业务

地区

业务USD

名称

营收

占比

Royalties

168.19M

63.50%

Sales of proprietary products

36.34M

13.72%

Sales of bulk rHuPH20

27.02M

10.20%

Sales-based milestones

15.00M

5.66%

Sales of device partnered products

14.68M

5.54%

Other

3.63M

1.37%

股东统计

更新时间: 7月29日周二

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.16%

The Vanguard Group, Inc.

10.39%

State Street Global Advisors (US)

4.91%

Snyder Capital Management, L.P.

2.98%

AllianceBernstein L.P.

2.61%

Other

66.94%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.16%

The Vanguard Group, Inc.

10.39%

State Street Global Advisors (US)

4.91%

Snyder Capital Management, L.P.

2.98%

AllianceBernstein L.P.

2.61%

Other

66.94%

股东类型

持股股东

占比

Investment Advisor

58.36%

Investment Advisor/Hedge Fund

30.60%

Research Firm

4.57%

Pension Fund

2.37%

Hedge Fund

1.88%

Bank and Trust

1.48%

Sovereign Wealth Fund

1.16%

Individual Investor

1.11%

Insurance Company

0.12%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1032

125.13M

101.55%

-10.49M

2025Q1

1043

127.91M

103.79%

-10.64M

2024Q4

999

127.73M

103.64%

-14.45M

2024Q3

953

129.39M

102.16%

-10.33M

2024Q2

905

126.24M

99.18%

-14.91M

2024Q1

870

127.71M

100.45%

-13.70M

2023Q4

850

128.82M

97.51%

-11.71M

2023Q3

836

127.73M

96.80%

-13.97M

2023Q2

838

128.24M

97.33%

-12.36M

2023Q1

833

129.53M

95.63%

-10.61M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

14.99M

12.16%

-268.69K

-1.76%

Mar 31, 2025

The Vanguard Group, Inc.

12.80M

10.39%

-451.45K

-3.41%

Mar 31, 2025

State Street Global Advisors (US)

6.05M

4.91%

-1.13M

-15.75%

Mar 31, 2025

Snyder Capital Management, L.P.

3.67M

2.98%

-494.15K

-11.85%

Mar 31, 2025

AllianceBernstein L.P.

3.22M

2.61%

+146.68K

+4.78%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.17M

2.57%

+105.17K

+3.43%

Mar 31, 2025

Macquarie Investment Management

2.67M

2.17%

-231.21K

-7.96%

Mar 31, 2025

Invesco Capital Management LLC

2.42M

1.96%

+628.59K

+35.15%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.03M

1.65%

+95.60K

+4.94%

Mar 31, 2025

Congress Asset Management Company, LLP

2.13M

1.73%

+172.97K

+8.83%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Future Fund Long/Short ETF

3.76%

First Trust NYSE Arca Biotechnology Index Fund

2.71%

Invesco Biotechnology & Genome ETF

2.54%

SPDR S&P Biotech ETF

2.35%

Congress SMid Growth ETF

2.21%

Janus Henderson Small Cap Growth Alpha ETF

2.05%

Invesco S&P MidCap 400 GARP ETF

1.92%

Janus Henderson Small/Mid Cap Growth Alpha ETF

1.92%

Virtus LifeSci Biotech Products ETF

1.84%

Alpha Architect US Quantitative Value ETF

1.84%

Future Fund Long/Short ETF

占比3.76%

First Trust NYSE Arca Biotechnology Index Fund

占比2.71%

Invesco Biotechnology & Genome ETF

占比2.54%

SPDR S&P Biotech ETF

占比2.35%

Congress SMid Growth ETF

占比2.21%

Janus Henderson Small Cap Growth Alpha ETF

占比2.05%

Invesco S&P MidCap 400 GARP ETF

占比1.92%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比1.92%

Virtus LifeSci Biotech Products ETF

占比1.84%

Alpha Architect US Quantitative Value ETF

占比1.84%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Halozyme Therapeutics Inc

59.745USD

Halozyme Therapeutics Inc

59.745

概览

公司

财务